Below are summaries of recently published analyses from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). Click on the shortened citations to access the publications.

Breast Cancer Screening – The Tomosynthesis Mammographic Imaging Screening Trial, or TMIST (EA1151), is ongoing and assessing 2D and 3D mammography in more than 108,000 women worldwide. Before TMIST, A4705 was a prospective mammography study conducted in women aged >40 at four Canadian sites. It served as a lead-in to help refine the parameters for the large-scale study to come. This analysis focuses on screening outcomes for the subgroup of A4705 participants ineligible for TMIST (which has a narrower age range of 45-74 years). TMIST Lead-In Randomized Trial of Breast Tomosynthesis Versus Digital Mammography: Results in Women Ineligible for the Full TMIST Trial Due to Age (40–44 or ≥ 74 Years Old). Seely JM. Am J Roentgenol. January 2026.

Cancer Care Delivery Research – There are many young women for whom immune checkpoint inhibitor therapy is the standard of care, yet the impact of this treatment on fertility is unknown and difficult to assess. In young women with melanoma treated with ipilimumab in the E1609 study, researchers observed hormonal changes suggesting reduced ovarian reserve, indicating that this treatment could potentially affect future fertility. The finding warrants further study. Impact of Immune Checkpoint Inhibition on Ovarian Reserve. Buchbinder EI. Oncologist. February 2026.

Head and Neck Cancer – E3311 demonstrated outstanding disease control after transoral surgery (TOS) with risk-based postoperative management in resectable HPV-associated head and neck cancer. Here, researchers assessed clinician-graded radiographic swallowing outcomes over time and across arms. Functional Impact of Transoral Surgery and Risk-Based Adjuvant Therapy in Human Papillomavirus-Associated Oropharyngeal Cancer: Swallowing Outcomes From ECOG-ACRIN E3311. Hutcheson KA. JCO Onc Adv. November 2025.

Hematologic Malignancies – Total body irradiation (TBI) is an essential component of allogeneic stem cell transplantation. A new technique, intensity-modulated radiation therapy (IMRT-TBI), may reduce toxicity and improve dose precision compared to traditional methods. However, large multi-center prospective trials are necessary to compare these approaches. This paper is a collaboration among ECOG-ACRIN and other cooperative groups within the National Clinical Trials Network (NCTN). Experts convened by NRG Oncology have developed a consensus-based framework for evaluating IMRT-TBI in future NCTN studies, to ensure consistent application and rigorous outcomes assessments. Incorporating Intensity Modulated Total Body Irradiation (IMRT-TBI) Into Future Cooperative Group Clinical Trials: An NRG Hematologic Malignancies Working Group-Led Report from the National Clinical Trials Network. Kovalchuk N. Int J Radiat Oncol Biol Phys. February 2026.

Leukemia – The latest translational science analysis to emerge from the practice-changing E1910 trial focuses on extramedullary disease, in which leukemic cells proliferate outside the bone marrow, forming tumors in tissues or organs. CRLF2-Rearrangement and Extramedullary Disease in B-Cell Acute Lymphoblastic Leukemia: A possible link?. Gava F. Blood Advances. February 2026.

Leukemia – Loss of CD25 in acute leukemia resulted in hyperactive oncogenic tyrosine kinase signaling that reduced cell fitness and leukemic potential. This translational science analysis utilizes data from study E2993. Dynamic Feedback Control of Oncogenic Tyrosine Kinase Signaling in Acute Leukemia. Lee J. Sci Signal. February 2026.